Radcliffe Department of Medicine

Desborough Group: Platelet disorders and transfusion

Curry Group: Endothelial regulation of haemostasis in health and disease

We study the mechanisms by which vascular endothelial cells regulate haemostasis in health and in acquired bleeding disorders, namely trauma-induced coagulopathy, to better understand disease pathogenesis and identify novel therapeutic targets.

Cancer target identification and development

Our research interests lie in studying the molecular mechanisms of tumour growth and the target development. We focus on the impact of metabolism and epigenetic regulation on crosstalk between stromal cells and tumour cells in the tumour microenvironment. The ongoing investigated tumours include colorectal cancer, breast cancer and cholangiocarcinoma.

Sahakyan Group: Integrative Computational Biology and Machine Learning

Combining computational biology, computational chemistry, and machine learning techniques with biological big data to unravel the higher genomic code of life.

Chakraverty Group: Haematopoietic Transplantation and Immunotherapy

Our group is interested in developing novel immunotherapeutic approaches for leukaemia. Clinical approaches currently used include allogeneic haematopoietic stem cell transplantation, chimeric antigen receptor T cell therapy and immune checkpoint inhibitors. While each of these approaches can be successful, they also fail in many patients as a result of tumour adaptations or diminished function of immune cells. Enhanced immunity can also lead to immune-related adverse events due to on- or off-target effects. We are exploring the mechanisms that underpin these failures and using this information to devise new strategies that can be translated into early phase clinical trials.

Psaila Group: The tumour microenvironment in blood cancers

We focus on four key areas: (1) Dissecting how blood cancers create 'self-reinforcing' niches that promote clonal expansion and protect malignant clones from immunotherapies; (2) Development and application of human bone marrow organoids to study normal and malignant haematopoiesis and validate targets in a relevant tissue microenvironment; (3) Developing novel strategies to selectively target cancer stem cells and pathological megakaryocytes in myelofibrosis, a severe bone marrow malignancy; (4) Understanding our recent discovery that platelets contain a repertoire of DNA fragments sequestered from cell free DNA, and confirming clinical utility for cancer detection and for pre-natal diagnosis.

Davies Group: Genomics and Clinical Genome Editing

We are primarily interested in understanding how the genome functions and to leverage this to develop novel genome editing based cellular therapies

Sauka-Spengler Group: Gene Regulatory Networks in Development and Disease

We focus on systems level “big picture” approaches to understand gene regulation and build gene regulatory networks during development and disease in zebrafish, chick, lamprey and human models.

de Bruijn Group: Developmental Haematopoiesis

We study the embryonic origins of blood stem cells with the aim to inform the generation of these cells in culture, and ultimate produce clinically relevant blood stem cells for therapeutic purposes.

Higgs Group: Laboratory of Gene Regulation

We use state-of-the-art laboratory and computational approaches to understand how mammalian genes are switched on and off during development and differentiation and how this goes awry in human genetic diseases.

Mead Group: Haematopoietic Stem Cell Biology

The Haematopoietic Stem Cell Biology (HSCB) Laboratory is focused on understanding how the normal haematopoietic stem/progenitor hierarchy is disrupted during the development of myeloid malignancies. Our overarching aim is to improve the management of myeloproliferative neoplasms and related conditions through better monitoring and therapeutic targeting of malignant stem cell populations.

Vyas Group: Biology and Treatment of Human Myeloid Cancers

We aim to understand the fundamental biological processes underlying normal and malignant haematopoiesis and translate this to improve patient outcomes through new rational therapies.

Kerr and Pezzella Group: Colorectal Clinical and Pathology Group

We lead colorectal cancer clinical trials, and study the basic biology of non-angiogenic and angiogenic tumours and mechanisms of vascular co-option.

Hughes Group: Genome Biology

Using genomics, computational and synthetic biology approaches to understand how genes are regulated in health and disease.

Gill and Hyde Group: Gene Medicine Group

We are developing gene therapy for lung conditions, including the genetic disease Cystic Fibrosis (CF) and neonatal lung conditions such as surfactant protein B (SPB) deficiency. We are also evaluating whether the lung can be used as a ‘protein factory’ to make therapeutic proteins such as antibodies.

Murphy, Roberts and Stanworth Group: Oxford Clinical Research in Transfusion Medicine

Increasing and disseminating the evidence-base to improve practice in Transfusion Medicine.

Goriely Group: Clinical genetics

We are using a human genetic approach that relies on the latest developments of Next Generation Sequencing technology to study the intimate relationship that exists between the occurrence of new mutations and the regulation of cell fate choices in the male germline. Because life-long production of sperm is supported by regular divisions of so-called spermatogonial stem cells, each one of us acquire ~30-100 new mutations in our genome, the majority of which is paternal in origin.

Boultwood Group: Blood Cancer UK Molecular Haematology Unit

We study the molecular mechanisms involved in disease initiation and progression in the myelodysplastic syndromes (MDS) in order to better understand disease pathogenesis and to identify new therapeutic targets and prognostic markers for this disorder.

Milne Group: Epigenetic Control of Gene Expression in Leukaemia and Haematopoiesis

Aberrant epigenetic changes are a driving force in many human cancers. The focus of our lab is centred on understanding how epigenetics impacts gene regulation so that this information can potentially be used to develop new therapeutic strategies.

Nerlov Group: Hematopoietic Stem Cell Genetics

Hematopoietic stem cell (HSC) transplantation is the only stem cell therapy in routine clinical use, and it is also the cell type that gives rise to most blood cancers. We use single cell biology and genetics to understand how hematopoietic stem cells normally sustain blood formation, and how this process is altered during ageing and when leukemia develops.

Search results

Found 21 matches for